Nucleus Network has recently opened its expanded facility in Sydney for Phase I clinical trials. Credit: Nucleus Network. There is no denying that Australia hits above its weight class in early ...

Moderna’s CEO Stéphane Bancel virtually attended the Financial Times Global Pharma and Biotech Summit on 10 November. Moderna’s mRNA-based vaccine intismeran in combination w ...

CRL has signed definitive agreements to acquire Frontage’s bioanalysis and DMPK operations in Exton, Pennsylvania for roughly $470m in cash.

Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.

Network Bio has entered into a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.

Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.

Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).

Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

This week's podcast features the Clinical Trials Arena team and GlobalData analysts who discuss the biggest study readouts from the ESMO Congress 2026.

Biotech investor Stephan Christgau speaks about the key considerations when devising a clinical strategy that will attract investor attention.